Home›Companies›Biotech & Pharma›INNOVOTEX

InnovoTEX Inc.

Develops cancer drugs designed to remain in tumors longer for people with cancer.

Updated Nov 9, 2026·Latest SEC filing Aug 18, 2026·Suggest an edit

About INNOVOTEX

INNOVOTEX is a private company based in Austin, Texas, incorporated in 2022 in Delaware. It has reported $3,625,315 raised in three offerings on Form D since March 2023. Its chief executive is Krystle Karoscik.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Mar 9, 2026Aug 18, 2026$75,000fully sold2$37,500DebtRule 506(b)Form D ↗
Nov 19, 2024Aug 6, 2026amended Aug 18, 2026$2,720,484of $4.0M target21$129KEquity, OptionsRule 506(b)Form D/A ↗1 earlier filing
Mar 21, 2023Mar 31, 2023amended Mar 31, 2023$829,831fully sold8$103KEquity, OptionsRule 506(b)Form D/A ↗1 earlier filing
Total, three offerings$3,625,315

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on INNOVOTEX's Form D filed Aug 18, 2026.

James Hussey
James Hussey
Executive Vice Chairman
Also CEO and director at Seneca Therapeutics.
Krystle Karoscik
Krystle Karoscik
Co-founder, CEO & Board Director
Jonathan Arambula
Jonathan Arambula
Co-founder, CTO & Executive Chairman

Earlier filings also listed Krystle Karosik (executive officer, last listed Mar 2023) and Joseph Arambula (ceo and president, director, last listed Mar 2023).

Sources

  1. SECInnovoTEX Inc. Form D, filed Aug 6, 2026
  2. SECInnovoTEX Inc. Form D, filed Mar 31, 2023
  3. SECInnovoTEX Inc. filing history